Search
Carboprost tromethamine
go.drugbank.com/drugs/DB00429ApprovedInvestigationalA nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy.
Geneticin
go.drugbank.com/drugs/DB04263ExperimentalResistance to Geneticin is conferred by the neo gene from Tn5 encoding an aminoglycoside 3‘-phosphotransferase, APH 3‘ II. … Geneticin (also known as G418) is an aminoglycoside antibiotic similar in structure to gentamicin B1, produced by Micromonospora rhodorangea.
Ribavirin
go.drugbank.com/drugs/DB00811ApprovedInvestigationalRibavirin is added to decrease relapse rates by accelerating viral clearance early in the treatment course [A19645].
TAK-428
go.drugbank.com/drugs/DB05499ExperimentalIt is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors.
Exemestane
go.drugbank.com/drugs/DB00990ApprovedInvestigationalExemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the ...
Lipegfilgrastim
go.drugbank.com/drugs/DB13200ApprovedSince July 2013, lipegfilgrastim is marketed by the EMA as Lonquex for subcutaneously injection, where it is administered once following cytotoxic chemotherapy for each chemotherapy cycle in adult patients
MEM 1414
go.drugbank.com/drugs/DB05888ExperimentalMEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of the brain where new memories are formed.
Arotinolol
go.drugbank.com/drugs/DB09204Investigational[T87] Artinolol is being developed by Sumitomo Pharmaceutical Co., Ltd. and it is currently under clinical trials.[L1168]
Inebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigationalInappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis … [L49861] In April 2025, inebilizumab was additionally approved by the FDA for immunoglobulin G4-related disease (IgG4-RD).[L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD.
AM103
go.drugbank.com/drugs/DB05225ExperimentalIt is being developed by Amira. … AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation